Alzamend Neuro regains Nasdaq listing compliance

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder, has regained compliance with Nasdaq listing requirements. The company met the minimum stockholders' equity requirement of $2.5 million under Nasdaq Listing Rule 5550(b)(1), as confirmed by a notification letter from Nasdaq dated Sunday.

Alzamend was previously notified in March 2026 that it did not meet the minimum market value of listed securities requirement for continued listing, given 45 calendar days to submit a compliance plan. CEO Stephan Jackman expressed satisfaction with the achievement, stating that maintaining the Nasdaq listing is crucial to the company's mission and appreciative of its investors' support.

Alzamend is currently conducting Phase II clinical trials for its drug candidate AL001 in partnership with Massachusetts General Hospital, with trials including cohorts for healthy humans, bipolar disorder, Alzheimer's, major depressive disorder, and post-traumatic stress disorder.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.